Literature DB >> 26636480

Maternal Serum Resistin Is Reduced in First Trimester Preeclampsia Pregnancies and Is a Marker of Clinical Severity.

Michael Christiansen1, Paula L Hedley1,2, Sophie Placing1, Karen R Wøjdemann3,4, Anting L Carlsen1, Jennifer M Jørgensen1, Anne-Cathrine Gjerris3,5, Anne-Cathrine Shalmi3,5, Line Rode3, Karin Sundberg3, Ann Tabor3.   

Abstract

OBJECTIVE: To examine whether resistin levels in first trimester maternal serum are associated with insulin resistance or preeclampsia (PE).
METHODS: A case-control study of maternal serum resistin concentration conducted using 285 normal pregnancies and 123 PE pregnancies matched for gestational age, parity and maternal age. Samples were taken in gestational weeks 10+0-13+6.
RESULTS: There was a negative correlation between resistin and clinical severity of PE, but no correlation with IS, TNF-α, body mass index, birth weight and pregnancy length.
CONCLUSIONS: Resistin is reduced in first trimester of PE pregnancies, particularly in severe PE. Inflammation and IS cannot explain this phenomenon.

Entities:  

Keywords:  placenta; pre-eclampsia; prenatal screening

Year:  2015        PMID: 26636480     DOI: 10.3109/10641955.2014.913615

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  3 in total

1.  Adipokine profiles in preeclampsia.

Authors:  Suchitra Chandrasekaran; Hayley Hunt; Susan Melhorn; Hilary S Gammill; Ellen A Schur
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-09

Review 2.  The Role of the Adipokines in the Most Common Gestational Complications.

Authors:  Paweł Gutaj; Rafał Sibiak; Maurycy Jankowski; Karina Awdi; Rut Bryl; Paul Mozdziak; Bartosz Kempisty; Ewa Wender-Ozegowska
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

3.  Circulating adipokine levels and preeclampsia: A bidirectional Mendelian randomization study.

Authors:  Xiaoyan Chen; Zhaoming Liu; Jingen Cui; Xiaolan Chen; Jing Xiong; Wei Zhou
Journal:  Front Genet       Date:  2022-08-22       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.